Bristol-Myers Squibb: How Does It Compare With Its Peers?
Bristol-Myers Squibb has a market cap of ~$100 billion. Within the Health Care Select Sector SPDR ETF’s (XLV) portfolio, it has a weight of 3.75%.
Out of 56 stocks in XLV’s portfolio, a total of 32 stocks were trading above their 20-day moving average.
Sorted by market cap, the Health Care Select Sector SPDR ETF’s (XLV) bottom ten stocks underperformed as of October 1, 2015.
Bristol-Myers and Celgene both gained on October 1, 2015, helping XLV’s top ten stocks perform better.
XLV outperformed the broader market representative SPDR S&P 50 ETF on October 1, 2015. SPY rose by 0.26% , compared with XLV’s 1.01%.
In March 2015, Perrigo acquired Omega Pharmaceuticals. adding many leading consumer healthcare brands to its existing portfolio.
The Base Plus Plus Plus business model has been instrumental in Perrigo’s commercial success despite tough competition from peers.
Perrigo offers diversified prescription pharmaceuticals, including generic and specialty prescription pharmaceuticals, in the US and UK.
Post-completion of its March 2015 acquisition of Omega, Perrigo has actively entered the European-branded OTC market.
Perrigo is a market leader in over-the-counter store-branded products. Its leadership position extends to major geographies such as the US, the UK, and Mexico.
Perrigo’s business model includes a well-aligned organizational structure of its segments and a strong product portfolio.
Perrigo is a leading healthcare supplier. It develops and distributes over-the-counter prescription pharmaceutical and nutritional products.
A strong business strategy coupled with solid financials have ensured that Novo Nordisk continues to trade at high valuation multiples.
Novo Nordisk (NVO) faces company-specific risks due to its unique business model. An over-reliance on diabetes increases the level of uncertainty associated with the company’s business.
To achieve its long-term targets, Novo Nordisk has consistently optimized operating expenses. It has reduced its cost of goods sold ratio as a percentage of sales from 20% in 2010 to 15% in 2014.
In April 2015, Novo Nordisk (NVO) announced positive results from a Phase 3 clinical trial of N8-GP (turoctocog alfa pegol), a hemophilia drug.
Novo Nordisk’s research and development pipeline includes three late-stage insulin studies of faster-acting insulin aspart, semaglutide, and LATIN T1D.
After North America, the International Operations region is Novo Nordisk’s (NVO) next main growth contributor. International Operations encompasses 153 countries around the world.
Novo Nordisk (NVO) generates 22.7% of its total revenues from the European market. It’s Novo Nordisk’s second largest market. China accounts for about 9.1% of the company’s total revenues.
North America, which includes the United States and Canada, is Novo Nordisk’s (NVO) largest market. It accounts for about 48% of the company’s total sales.